Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121566) titled 'Low-Dose Radiotherapy Plus Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Controlled Trial' on April 1.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: West China Hospital of Sichuan University
Condition:
Esophageal squamous cell carcinoma
Intervention:
Control group:Two cycles of anti-PD-1 therapy (tislelizumab) combined with chemotherapy as neoadjuvant treatment
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollment: 2026-04-01
Target Sample Size: Control group:96;Experimental gro...